CN101040889A - Traditional Chinese medicinal prepns. for treating osteoporosis - Google Patents
Traditional Chinese medicinal prepns. for treating osteoporosis Download PDFInfo
- Publication number
- CN101040889A CN101040889A CN 200610065215 CN200610065215A CN101040889A CN 101040889 A CN101040889 A CN 101040889A CN 200610065215 CN200610065215 CN 200610065215 CN 200610065215 A CN200610065215 A CN 200610065215A CN 101040889 A CN101040889 A CN 101040889A
- Authority
- CN
- China
- Prior art keywords
- herba epimedii
- chinese medicine
- total flavones
- medicine preparation
- epimedii total
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 25
- 229930003944 flavone Natural products 0.000 claims abstract description 39
- 235000011949 flavones Nutrition 0.000 claims abstract description 39
- 150000002213 flavones Chemical class 0.000 claims abstract description 38
- 238000002360 preparation method Methods 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 22
- 239000002775 capsule Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 claims description 2
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 235000015091 medicinal tea Nutrition 0.000 claims description 2
- 230000001009 osteoporotic effect Effects 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 229920001353 Dextrin Polymers 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 claims 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- 150000002212 flavone derivatives Chemical class 0.000 claims 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims 1
- 241001016310 Epimedium grandiflorum Species 0.000 abstract description 4
- 235000018905 epimedium Nutrition 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 3
- 239000000470 constituent Substances 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 description 26
- 239000011575 calcium Substances 0.000 description 21
- 210000003734 kidney Anatomy 0.000 description 18
- 229910052791 calcium Inorganic materials 0.000 description 16
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 102000007591 Tartrate-Resistant Acid Phosphatase Human genes 0.000 description 10
- 108010032050 Tartrate-Resistant Acid Phosphatase Proteins 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 102000019197 Superoxide Dismutase Human genes 0.000 description 7
- 108010012715 Superoxide dismutase Proteins 0.000 description 7
- 230000037182 bone density Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 229910052698 phosphorus Inorganic materials 0.000 description 6
- 208000006386 Bone Resorption Diseases 0.000 description 5
- 230000024279 bone resorption Effects 0.000 description 5
- 210000000689 upper leg Anatomy 0.000 description 5
- 239000010949 copper Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000009040 gushukang Substances 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000011572 manganese Substances 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 210000002997 osteoclast Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 229910052748 manganese Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229960004618 prednisone Drugs 0.000 description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241001362421 Epimedium brevicornu Species 0.000 description 1
- 241000893531 Epimedium koreanum Species 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020674 Hypermetabolism Diseases 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000002436 femur neck Anatomy 0.000 description 1
- -1 filter Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 206010041569 spinal fracture Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a Chinese medicament for treating osteoporosis and its preparation process, wherein the main active constituents of the medicament include barrenwort flavones. The medicament is prepared from barrenwort flavones and pharmacologically acceptable auxiliary materials.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation, belong to new Chinese medicine research and development field with function of resisting osteoporosis.
Background technology
Osteoporosis is a kind of common disease, and sickness rate is the highest in elderly population.And along with the growth in population life-span, increasing of old number, the harm of this disease reveals gradually, vertebral fracture causes pain and deformity, the femoral neck bone fracture needs hospitalization, often also have severe complications or cause death, the people is arranged even can cause permanent afunction, these have all brought great economic loss to society.The people in life, the bone amount that final male loses reaches 25～35%, the women can be up to 45～55%, its bone amount of nephrasthenia syndrome patient is than person who suffer from deficiency of kidney Yang is not low.
At osteoporosis, the modern times clinically medication Diphosphonate, special estrogenic agents, calcitonin, estrogen, parathormone etc. are arranged, belong to Western medicine, have toxic and side effects, and the life-time service safety is also unclear.Be the naturopathic epoch of advocating drug safety at present, Many researchers is placed on treatment by Chinese herbs disease aspect to sight.But the research for the function of resisting osteoporosis Chinese medicine preparation rests on traditional compound preparation conceptual phase more, and dosage is bigger, is inconvenient to take, and a lot of curative effects all can not be satisfactory.
Herba Epimedii is the dry aerial parts of Radix Berberidis Amurensis plant Epimedium Epimedium Brevicornum.Summer, autumn tap when stem, leafiness, remove thick stalk and impurity, dry or dry in the shade.Kind surplus global barrenwort has 40 mainly is distributed in the temperate zone and the subtropical zone in Asia, the Middle East, Europe.Homemade Herba Epimedii has 23 kinds and 4 mutation now, wherein have the distribution in the NORTHERN KOREA area except that Herba Epimedii E.koreanum, all the other are China endemic species, are dispersed throughout all parts of the country, distributed more widely with the Yangtze river basin, wherein Sichuan and Guizhou two provinces respectively are distributed with 13 kinds.Shennong's Herbal is classified them as middle product, and Li Shizhen (1518-1593 A.D.) claims the effect that it has " beneficial vital essence, hard muscle, benefit waist knee joint, heart tonifying power " in Compendium of Material Medica, and " it is certified products that Chinese pharmacopoeia version in 1985 has been collected these genus four kind of plant.
According to pharmacopeia record, the extract of Herba Epimedii has kidney-replenishing, bone and muscle strengthening, the effect of wind-damp dispelling, and osteoporosis is a kind of and aging and the relevant osteopathia of bone calcium loss, the traditional Chinese medical science is thought, the kidney generating marrow and dominating bone, kidney and bone are in close relations, and the while kidney is closely related with aging again.Suffering from a deficiency of the kidney itself is old and feeble result, and it also can become causes old and feeble reason, suffers from a deficiency of the kidney and can directly or indirectly cause a large amount of losses of bone calcium; Osteoporosis is one of traditional Chinese medical science arthromyodynia, suffers from a deficiency of the kidney and the atrophic debility of bones, suffer from a deficiency of the kidney and osteodynia, and be main pathogenesis to suffer from a deficiency of the kidney, expectorant stasis of blood resistance arteries and veins is a promoting factor.Therefore, primary osteoporosis, secondary osteoporosis such as osteofluorosis etc. come from suffer from a deficiency of the kidney, insufficiency of vital energy and blood.Treatment then should be started with from the kidney invigorating, reaches the effect for the treatment of both the principal and secondary aspects of a disease by the kidney invigorating.
Summary of the invention
The purpose of this invention is to provide a kind of pure Chinese medicine pharmaceutical preparation that contains Herba Epimedii total flavones, be used for the treatment of osteoporosis.
The present invention is according to theory of Chinese medical science: the kidney generating marrow and dominating bone, and kidney and bone are in close relations, and kidney is closely related with aging again simultaneously, and suffering from a deficiency of the kidney itself is old and feeble result, and it also can become causes old and feeble reason, and directly or indirectly causes a large amount of losses of bone calcium.The present invention starts with from the kidney invigorating, by the kidney invigorating and then reach the curative effect of osteoporosis, has developed a kind of Chinese medicine preparation with function of resisting osteoporosis by a large amount of pharmacology, the test of pesticide effectiveness.
The present invention is made by the raw material of following weight portion:
Herba Epimedii total flavones 10-70%
Pharmaceutic adjuvant 30-90%
Herba Epimedii total flavones of the present invention can be by disclosed preparation method preparation in this area, and the present invention provides a kind of feasible preparation method at this: get Korea barren wort medicinal material, use 70% alcohol reflux.Filter, concentrated, with dissolved in distilled water, filter, filtrate is crossed the D-101 macroporous adsorptive resins, washes with 5 times of resinite hydrops earlier, and 70% ethanol of 6 times of resin volumes of reuse is collected eluent, and decompression recycling ethanol concentrates, and vacuum drying gets Herba Epimedii total flavones.The content of Herba Epimedii total flavones is more than 50%, and content Determination of Icariin is more than 15%.
The present invention adopts described method of embodiment or pharmaceutics prior art that the pharmaceutic adjuvant of accepting on described Herba Epimedii total flavones and the pharmaceutics is prepared into capsule, tablet, oral liquid, granule, pill, medicinal tea or Emulsion.Wherein preferred dosage form is a capsule.
The preparation method of capsule of the present invention comprises the steps: to get Herba Epimedii total flavones, grinds, and crosses 80 mesh sieves.Add pharmaceutic adjuvant, sieve mix homogeneously.Be sub-packed in the capsule, packing, promptly.
The present invention sets forth useful effect of the present invention by the following test of pesticide effectiveness:
(1) Herba Epimedii total flavones is to the influence of osteoporosis rat model due to the prednisone
Irritate stomach and give rat acetic acid prednisone (PAT), make the formation osteoporosis, irritate simultaneously stomach give Herba Epimedii total flavones little (50mg/kg), in (100mg/kg), big (150mg/kg) three dosage, femoral bmd (BMD), biochemical indicator and the trace element of measuring administration 13 all animals change.The results are shown in Table 1, table 2, table 3.The result shows: three dosage of Herba Epimedii total flavones cause osteoporosis rat to prednisone and improve significantly.
Table 1: Herba Epimedii total flavones is to the influence of rat femur bone density (BMD) (x ± s)
| Group | Dosage (mg/kg) | n | BMD (g/cm2) | |
| Blank group model matched group GUSHUKANG group | 3000 | 15 14 11 | 0.339±0.027 0.314±0.021 △ 0.336±0.022 * | |
| Excessive sheep | Small dose group | 50 | 15 | 0.325±0.024 |
| Leaves of pulse plants total flavones | The heavy dose of group of middle dosage group | 100 150 | 13 15 | 0.334±0.023 * 0.337±0.0155 ** |
Annotate: compare with the blank group,
△P＜0.05; Compare with model group,
*P＜0.05,
*P＜0.01.
The bone density of model group has been compared significance decline (P＜0.05) with the blank group, the GUSHUKANG group is compared bone density and is significantly raise (P＜0.05) with model group, big or middle dosage group of Herba Epimedii total flavones and model group comparison bone density have remarkable rising (P＜0.05 or P＜0.01).
Table 2 Herba Epimedii total flavones is to the influence of Serum from Model Rats with Osteoporosis TRAP, ALP, Ca, P and SOD (x ± s)
| Group | Dosage mg/kg | n | TRAP (U/L) | ALP (U/L) | Ca (mmol/L) | P (mmol/L) | SOD (NU/ml) | |
| Blank group model matched group GUSHUKANG group | 3000 | 15 13 11 | 3.17± 0.24 4.09± 0.47 △△△ 3.19± 0.11 *** | 45.88± 7.00 59.76± 16.66 △△ 58.16± 8.22 | 2.61± 0.27 2.39± 0.24 △ 2.64± 0.35 | 2.01± 0.39 1.88± 0.31 1.81± 0.18 | 230.5± 24.4 131.6± 41.2 △△△ 181.9± 31.3 ** | |
| Herba Epimedii total flavones | The heavy dose of group of dosage group in the small dose group | 50 100 150 | 14 13 15 | 4.09± 0.08 3.78± 0.10 * 3.43± 0.42 *** | 58.95± 13.43 54.06± 12.03 45.28± 10.85 * | 2.63± 0.36 2.72± 0.29 ** 2.86± 0.45 ** | 1.99± 0.57 1.77± 0.34 1.84± 0.26 | 143.9± 26.1 163.4± 29.4 * 202.3± 44.0 *** |
Annotate: compare △ P＜0.05 with the blank group; Compare * P＜0.05, * * P＜0.01, * * * P＜0.01 with model group.
TRAP: tartrate-resistant acid phosphatase; ALP: alkali phosphatase; SOD: superoxide dismutase.
Compare with the blank group, serum T RAP, the ALP of model group significantly raises (P＜0.01 or P＜0.05), and serum Ca and SOD significantly reduce (P＜0.01 or P＜0.001); Compare with model group, positive controls TRAP, SOD significantly reduce (P＜0.01 or P＜0.001); Compare with model group, the serum T RAP of the big or middle dosage group of Herba Epimedii total flavones significantly reduces (P＜0.01 or P＜0.001), the serum levels of ALP of heavy dose of group significantly reduces (P＜0.05), the serum Ca and the SOD of big or middle dosage group significantly raise (P＜0.01 or P＜0.05 or P＜0.001).
Table 3 Herba Epimedii total flavones is to the influence of osteoporosis rat model femur calcium, phosphorus and trace element (x ± s)
| Group | Dosage mg/kg | n | Ca (％) | P (％) | Mg (mg/kg) | Zn (mg/kg) | Mn (mg/kg) | Cu (mg/kg) | |
| Blank group model matched group GUSHUKANG group | 3000 | 15 14 11 | 4.91± 0.12 4.57± 0.31 △△△ 4.96± 0.13 *** | 3.40± 0.37 3.12± 0.19 △ 3.60± 0.40 ** | 3786.6± 166.8 3845.5± 171.9 3765.4± 143.4 | 497.2± 126.8 518.6± 123.3 467.7± 106.5 | 29.08± 0.71 28.35± 0.78 △ 31.88± 1.19 *** | 29.92± 0.90 29.14± 0.89 △ 29.05± 0.64 | |
| Herba Epimedii total flavones | The heavy dose of group of dosage group in the small dose group | 50 100 150 | 14 13 15 | 4.84± 0.21 * 4.91± 0.17 ** 4.95± 0.10 *** | 3.32± 0.29 * 3.37± 0.24 ** 3.60± 0.37 *** | 3719.6± 330.3 3875.2± 133.5 3872.9± 174.4 | 495.7± 93.0 522.0± 99.9 501.6± 108.0 | 29.41± 0.53 *** 28.97± 0.44 * 30.94± 1.01 *** | 28.41± 0.62 * 28.52± 0.40 * 28.60± 0.52 |
Annotate: compare with the blank group,
△P＜0.05,
△ △ △P＜0.001; Compare with model group,
*P＜0.05,
*P＜0.01,
* *P＜0.01.
Compare with the blank group, rat femur Ca, the P of model group, Mn, Cu all have significance to reduce (P＜0.05, P＜0.001); Compare with model group, positive controls rat femur Ca, P, Mn all have significance rising (P＜0.01 or P＜0.001); Compare with model group, femur Ca, P, Mn, the Cu of the large, medium and small dosage group of Herba Epimedii total flavones has significant difference (P＜0.05, P＜0.01 or P＜0.001) in various degree.
But glucocorticoid medicine induced osteoporosis such as prolonged application prednisolone acetate, it is by reducing sex hormones secretion, secondary causes hyperparathyroidism, cause inhibition of intestinal calcium absorption and renal tubules that calcium is heavily absorbed and reduce the direct influence a plurality of approach such as (comprise and suppress bone formation and strengthen bone resorption) that reach bone, cause that bone density reduces, bone mineral content reduces; Bone resorption is hyperfunction, and bone calcium is released into blood, and UCaE increases, and ossein is decomposed acceleration, and urinary hydroxyproline rises.
Originally studies show that its bone density obviously increases, and illustrates that Herba Epimedii total flavones can increase animal pattern bone amount with the rat after the Herba Epimedii total flavones treatment; The content of the amount of trace element such as calcium, phosphorus reflection bone mineral in the bone mineral, osteoclast is at first removed mineral, carries out bone gelatin subsequently and decomposes.So showing as dissolving of tangible bone ore deposit and calcium content of bone during osteoporosis descends.Herba Epimedii total flavones can improve micronutrient levelss such as calcium in the bone, phosphorus, manganese, copper, illustrates that it can suppress the dissolving in bone ore deposit and loses; Simultaneously Herba Epimedii total flavones can significantly increase the body blood calcium, illustrates that it can obviously improve negative calcium balance, improves calcium loss.
Tartrate-resistant acid phosphatase in the serum (TRAP) mainly is to be discharged in the blood by osteoclast, the level of TRAP can reflect the activity of osteoclast and the state of bone resorption basically in the blood, and osteoporosis rat can show as the TRAP level that discharges in the body blood to be increased.The TRAP level obviously reduces in the osteoporosis rat blood with making after the Herba Epimedii total flavones treatment, illustrates that it can suppress osteoclast activity, reduces bone resorption.
Blood neutral and alkali phosphatase 50% derives from bone, the ALP activity can reflect the osteoblast activity, and ALP content all raise when bone formation or bone resorption were hyperfunction, and this experiment shows that Herba Epimedii total flavones can reduce the ALP activity, the prompting Herba Epimedii total flavones can improve the hypermetabolism state of bone, increases the formation of bone.
In sum, Herba Epimedii total flavones can effectively be prevented and treated the osteoporosis that hormone brings out, and shows as bone density improving, reduces the bone conversion.
The specific embodiment:
The present invention specifies the preparation method of the pharmaceutical preparation with function of resisting osteoporosis by following examples, but the present invention is not limited to the content that the following example comprises.
Embodiment 1:
Get Herba Epimedii total flavones 100g and grind, the microcrystalline Cellulose 98g of adding and micropowder silica gel 2g cross 80 mesh sieves three times, mix homogeneously.Be sub-packed in the capsule, promptly.
Embodiment 2:
Get Herba Epimedii total flavones 100g and grind, add pregelatinized Starch 49g, microcrystalline Cellulose 49g and micropowder silica gel 2g, cross 80 mesh sieves three times, mix homogeneously.Be sub-packed in the capsule, promptly.
Embodiment 3:
Get Herba Epimedii total flavones 25g and grind, add microcrystalline Cellulose 78g and carboxylic first class Starch Sodium 20g and mix evenly, use 60% alcohol granulation, 60 ℃ of dryings, granulate, with magnesium stearate 2g, mix homogeneously, tabletting are promptly.
Embodiment 4:
Get Herba Epimedii total flavones 100g and grind, add pregelatinized Starch 87g and lactose 60g and mix evenly, use 95% alcohol granulation, 60 ℃ of dryings, granulate, with magnesium stearate 3g, mix homogeneously is made granule promptly.
Claims (8)
1, the osteoporotic Chinese medicine preparation of a kind of treatment is characterized in that said preparation is to be prepared from by acceptable auxiliary on Herba Epimedii total flavones and the pharmaceutics.
2, Chinese medicine preparation according to claim 1 is characterized in that content of total flavone is more than 50% in the Herba Epimedii total flavones, and wherein content Determination of Icariin is greater than 15%.
3, Chinese medicine preparation according to claim 1 is characterized in that consisting of of Herba Epimedii total flavones and pharmaceutic adjuvant two components: Herba Epimedii total flavones 10-70%, pharmaceutic adjuvant 30-90%.
4, Chinese medicine preparation according to claim 1, it is characterized in that pharmaceutic adjuvant be selected from medical starch, pregelatinized Starch, beta-schardinger dextrin-, carboxylic first class Starch Sodium, lactose, dextrin, micropowder silica gel or the microcrystalline Cellulose any or several.
5, Chinese medicine preparation according to claim 1 is characterized in that said preparation can be capsule, tablet, oral liquid, granule, pill, medicinal tea or Emulsion.
6, Chinese medicine preparation according to claim 5, the preferred dosage form that it is characterized in that said preparation is a capsule.
7, Chinese medicine preparation according to claim 6 is characterized in that the preparation method of capsule comprises the steps: to get Herba Epimedii total flavones, grinds, and crosses 80 mesh sieves.Add pharmaceutic adjuvant, sieve mix homogeneously.Be sub-packed in the capsule, packing, promptly.
8, the application of the described Chinese medicine preparation of the arbitrary claim of claim 1～6 in preparation treatment medicine for treating osteoporosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100652157A CN101040889B (en) | 2006-03-20 | 2006-03-20 | Traditional Chinese medicinal prepns. for treating osteoporosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100652157A CN101040889B (en) | 2006-03-20 | 2006-03-20 | Traditional Chinese medicinal prepns. for treating osteoporosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101040889A true CN101040889A (en) | 2007-09-26 |
| CN101040889B CN101040889B (en) | 2010-10-27 |
Family
ID=38806818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006100652157A Expired - Fee Related CN101040889B (en) | 2006-03-20 | 2006-03-20 | Traditional Chinese medicinal prepns. for treating osteoporosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101040889B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101485726B (en) * | 2008-01-14 | 2011-04-13 | 浙江省新华医院 | Chinese medicine for osteoporosis and healing waistband |
| CN104095863A (en) * | 2014-08-06 | 2014-10-15 | 国药集团国瑞药业有限公司 | Pharmaceutical composition containing zoledronic acid and preparation thereof |
| CN105663239A (en) * | 2016-03-08 | 2016-06-15 | 宁夏医科大学 | Application of cinnamomum burmannii leaf extract in preparation of medicine used for treating osteoporosis and pharmaceutical composition of cinnamomum burmannii leaf extract |
| CN105687317A (en) * | 2016-03-08 | 2016-06-22 | 宁夏医科大学 | Application of total flavonoids in leaves of cinnamomum burmanni in preparation of medicine for treating osteroporosis and medicine composition |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1176677C (en) * | 2001-05-23 | 2004-11-24 | 周亚伟 | Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and its preparing process |
-
2006
- 2006-03-20 CN CN2006100652157A patent/CN101040889B/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101485726B (en) * | 2008-01-14 | 2011-04-13 | 浙江省新华医院 | Chinese medicine for osteoporosis and healing waistband |
| CN104095863A (en) * | 2014-08-06 | 2014-10-15 | 国药集团国瑞药业有限公司 | Pharmaceutical composition containing zoledronic acid and preparation thereof |
| CN104095863B (en) * | 2014-08-06 | 2016-03-30 | 国药集团国瑞药业有限公司 | A kind of pharmaceutical composition and preparation thereof comprising zoledronic acid |
| CN105663239A (en) * | 2016-03-08 | 2016-06-15 | 宁夏医科大学 | Application of cinnamomum burmannii leaf extract in preparation of medicine used for treating osteoporosis and pharmaceutical composition of cinnamomum burmannii leaf extract |
| CN105687317A (en) * | 2016-03-08 | 2016-06-22 | 宁夏医科大学 | Application of total flavonoids in leaves of cinnamomum burmanni in preparation of medicine for treating osteroporosis and medicine composition |
| CN105687317B (en) * | 2016-03-08 | 2021-01-01 | 宁夏医科大学 | Application of total flavonoids of cinnamomum burmannii leaves in preparation of medicine for treating osteoporosis and medicine composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101040889B (en) | 2010-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101062372A (en) | Chinese herbal medicine preparation for dissolving hepatobiliary system calculi | |
| CN101040889B (en) | Traditional Chinese medicinal prepns. for treating osteoporosis | |
| CN1284567C (en) | Medicinal liquid for treating osteoporosis and its preparation method | |
| CN102671178B (en) | Preparation method of Chinese medicinal composition for treating nephrotic syndrome and uremia and application thereof | |
| CN1660196A (en) | Extractive of Chinese traditional medicine prepared from epimedium and drynaria, and method for producing preparation | |
| CN1742775A (en) | Medicine composition for preventing and treating orthopedic diseases | |
| CN102106980B (en) | Medicament for treating uremia and preparation method thereof | |
| CN1232279C (en) | Antilipemic Chinese medicine | |
| CN1742904A (en) | Chinese medicine for treating urinary stone and urinary system inflammation, and production method thereof | |
| CN1250253C (en) | Chinese medicine capsule for treating ischemic cerebral apoplexy | |
| CN1781538A (en) | Chinese medicine preparation for treating mephritis and nephrosis syndrome | |
| CN100345571C (en) | Medication for treating necrosis of femoral head and preparation method | |
| CN1899574A (en) | Chinese medicine composition for preventing and controlling liver cancer and its use | |
| CN1186067C (en) | Medicine for curing acute injury of muscle and tendon and its preparation method | |
| CN100484542C (en) | Chinese medicinal compound recipe for treating osteoporosis and its preparing process | |
| CN102406792B (en) | Pharmaceutical composition for rapidly promoting healing of bone fracture | |
| CN1059104C (en) | Capsule for anti hepatitis B | |
| CN107260780B (en) | Traditional Chinese medicine composition for treating rheumatic arthritis | |
| CN101007113B (en) | Shenling Chinese medicine preparation for treating acute and chronic hepatitis and its preparation method | |
| CN101317958A (en) | Medicament for treating uarthritis, that is Tongfengning capsule and preparation method thereof | |
| CN1814153A (en) | Medicine composition for preventing and treating breast cancer and preparing method | |
| CN1158093C (en) | Medicine composition containing yak bone for treating rhenmatism and method for making same | |
| CN1253179C (en) | Drug for treating ischemic necrosis of femoral head | |
| CN1126558C (en) | Medicine for treating kidney damage caused by immunological disease lupus erythematosus | |
| CN1088370C (en) | Tongguanshugan ointment and preparation process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: ZHEJIANG HACON PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHOU YAWEI Effective date: 20111103 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100084 HAIDIAN, BEIJING TO: 310018 HANGZHOU, ZHEJIANG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20111103 Address after: 310018 No. 266, No. 12, Hangzhou economic and Technological Development Zone, Zhejiang Province Patentee after: Zhejiang Hangzhou Pharmaceutical Co., Ltd. Address before: 100084, Beijing, Zhongguancun, Haidian District North 123 Avenue, branch office incubator room 2206 Patentee before: Zhou Yawei |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101027 Termination date: 20180320 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |